Eliquis Lawsuit: Lawyers for Eliquis Bleeding Problems #cerebral #palsy #lawsuit


Eliquis Lawsuit

Eliquis Injury and Bleeding Risks

Eliquis was the third member of a new class of oral anticoagulants, known as Factor Xa inhibitor, which also includes the medications Pradaxa and Xarelto. It was developed by Pfizer and Bristol-Myers Squibb, and has been aggressively promoted in direct-to-consumer advertisements.

Approved by the FDA in December 2012, Eliquis is prescribed to reduce the risk of blood clots. It is promoted as a superior replacement for Coumadin, sold generically as Warfarin, which has been the leading anticoagulant for decades. However, users may face a substantial risk of suffering severe injury or wrongful death from bleeding problems on Eliquis, which was not adequately disclosed on the drug label.

Shortly after the medication was introduced, reports of Eliquis bleeding problems began to surface, raising similar concerns to those linked to Xarelto side effects and Pradaxa side effects .

While doctors are able to quickly reverse the effects of warfarin if bleeding develops, there was no approved antidote for Eliquis, Pradaxa or Xarelto at the time these new medications were introduced.

This may cause uncontrollable bleeding, resulting in:

  • Extended Hospitalization
  • Intensive Care Treatment (ICU)
  • Blood Transfusions
  • Wrongful Death

Recent studies have also raised questions about claims by the drug makers that Eliquis does not require blood monitoring, as it is possible such recommendations may have helped doctors identify individuals who may be at risk of bleeds on Eliquis.

Due to a lack of adequate warnings provided by the drug makers, many individuals have suffered severe bleeding complications, where doctors were unable to stop blood loss.

Eliquis Problems

The study used to approve Eliquis, ARISTOTLE. was published in 2012 in the New England Journal of Medicine. However, it immediately came under fire by the journal s former editor, Dr. Arnold Relman, as an example of how corporate backing can lead to skewed study results.

In a Forbes article published in September 2011, Dr. Relman noted that the study compared the safety and efficacy of Eliquis to warfarin. However, he pointed out that what the study authors did not mention in the article outlining the results was that more than a third of the patients were not given an actual therapeutic dose of Warfarin, which could explain why Warfarin appeared to have a higher rate of blood clots and strokes than those given Eliquis.

Others have pointed out that the study s findings failed to mention at least one patient death. There are also concerns that the researchers, funded by Bristol Myers-Squibb, falsified data and intentionally lost records just before an FDA inspection under orders from a company employee.

According to allegations raised in Eliquis lawsuits, there was been no adequate testing of the safety or efficacy of of the drug prior to promoting the medication for use by individuals throughout the United States.

Eliquis Failure to Warn Lawsuit Allegations

The product liability lawyers at Saiontz Kirk, P.A. are reviewing potential Eliquis class action and individual injury lawsuits on behalf of individuals who have suffered severe and debilitating bleeding injuries after being prescribed the anticoagulant.

Some of the lawsuit allegations raised against manufacturers include:

  • Failure to Adequately Research the Eliquis Bleeding Side Effects;
  • Failure to Warn About the Risk of Uncontrollable Bleeding on Eliquis;
  • Failure to Properly Investigate Reports of Bleeding Problems After Eliquis was Introduced;
  • Failure to Identify an Eliquis Reversal Agent Before Introducing the Drug;
  • Failure to Recommend Eliquis Blood Monitoring For Patients;
  • Failure to Issue an Eliquis Recall or Updated Warnings Following Reports of Bleeding Problems;
  • Placing Profits Before the Interests and Safety of Consumers.

Also Investigating Bleeding Lawsuits For:


Pradaxa (dabigatran) was the first member of this new class of anticoagulants, introduced by Boehringer Ingelheim in October 2010. Shortly after the medication hit the market, it was linked to a surprising number of severe bleeding problems and wrongful deaths.

Following several years of litigation, millions were paid in Pradaxa settlements. However, as additional reports of bleeding problems continue to surface, Pradaxa cases continue to be filed by individuals nationwide.


Bayer Healthcare and Janssen Pharmaceuticals face thousands of lawsuits over Xarelto side effects, raising similar allegations to those that will be presented in Eliquis cases.

Xarelto (rivaroxoaban) was introduced in 2011, and became the most widely used drug out of the new class of novel oral anticoagulants. As more people were switched to this new drug, increasing reports of Xarelto bleeding problems surfaced, often resulting in severe injury or wrongful death.

No Fees or Expenses Unless You Receive an Eliquis Settlement

As a result of the drug maker s apparent decision to place their desire for profits before consumers safety, financial compensation may be available through an Eliquis injury settlement.

Saiontz Kirk, P.A. is a nationally known injury law firm that is focused exclusively on representing individuals, we do not represent corporations or insurance companies. Over the course of more than 40 years, our personal injury lawyers have collected more than $1 billion in compensation for our clients in cases of medical malpractice, automobile accidents, product liability and other personal injury lawsuits.

All Eliquis lawsuits will be handled by our attorneys on a contingency fee basis, which means that there are never any out-of-pocket expenses to hire our law firm and we only receive a fee if compensation is secured for our client.

Protect your family and find out if you or a loved one may be eligible to pursue an Eliquis injury case. Request a free consultation and claim evaluation.

Helping Personal Injury Clients

40 Years Experience

  • On Behalf of Our Clients

  • No Recovery, No Fee

    No Fees/Expenses Unless We Win

    Steps to Find Out If You Have a Case:

    Contact Saiontz Kirk

    To Find Out If You May Have A Case, Contact Saiontz Kirk, P.A. By Calling Toll Free at 1-800-522-0102 .A Free Consultation and Case Evaluation Can Also Be Obtained By Completing Our On-Line Request Form Below.

    Review Your Case

    During a Free Consultation and Claim Evaluation, Saiontz Kirk, P.A. Will Review the Circumstances Surrounding Your Case and Help Determine Whether Financial Compensation May Be Available.You Will Have an Opportunity to Speak with a Lawyer and Review Any Questions or Concerns Before Moving Forward With a Case.

    Decide to Hire a Lawyer

    After Saiontz Kirk, P.A. Agrees to Take Your Case, It Remains Your Decision Whether To Hire Our Law Firm.There Are Never Any Out-of-Pocket Costs and We Receive No Attorney Fees or Expenses Unless a Recovery is Obtained.

    Obtain a Free Eliquis Lawsuit Evaluation

    To request a free consultation and Eliquis case evaluation with the lawyers at Saiontz Kirk, P.A. complete the form below and provide information about your claim. Our law firm can also be reached toll free at 1-800-522-0102 .

    During the case evaluation, Saiontz Kirk, P.A. will review the circumstances surrounding the injury and help determine whether financial compensation or a Eliquis settlement may be available. You will have an opportunity to speak with a lawyer and review any questions or concerns before moving forward with a case.

    Provide Complete Contact Information and Details About Your Case

    DISCLAIMER: By submitting a request for a free consultation and claim evaluation, you are not retaining an attorney. No attorney-client relationship is formed until a case is accepted by our office and a contingency fee agreement is signed. In some cases, Saiontz Kirk, P.A. may associate with outside attorneys as lead counsel, at no additional cost to the client. There is no obligation to retain our services.

  • Leave a Comment

    Your email address will not be published. Required fields are marked *